Cerecor's COVID-19 Drug Gets FDA Fast Track Designation
07:53 AM EDT, 05/11/2021 (MT Newswires) -- Cerecor (CERC) said Tuesday that its investigational COVID-19 drug CERC-002 has been given fast-track designation by the Food and Drug Administration.
The FDA's fast track tag helps speed up development and review of drugs with the potential to treat serious or life-threatening conditions with an unmet medical need.
CERC-002 is eligible for both rolling submission and priority review under the fast track status, Cerecor said.
The company said CERC-002 is an anti-LIGHT, or tumor necrosis factor superfamily member 14, antibody licensed from Kyowa Kirin and being developed to treat Crohn's disease in children and respiratory disease caused by cytokine storm induced COVID-19.
Shares climbed 15% in premarket trading.
Price: 3.0500, Change: +0.51, Percent Change: +20.08